Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coiled-coil domain-containing protein 167 (CCDC167) is a membrane-associated protein upregulated in various cancers, most notably breast cancer, where high expression correlates with poor prognosis. CCDC167 is involved in cell cycle progression, ubiquitination, mitosis, and is regulated by multiple oncogenic networks. Knockdown or inhibition of CCDC167 suppresses cancer cell proliferation and tumor progression, suggesting CCDC167 as a candidate therapeutic target and a negative prognostic marker in breast cancer. The gene is affected by common chemotherapeutic agents, highlighting its potential as a biomarker and modulator of drug response in oncology.
Downregulation of CCDC167 by cytotoxic and chemotherapeutic agents suppresses cancer cell proliferation and tumor progression
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coiled-coil domain-containing protein 167 (CCDC167).